Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The expression of interleukin-1-receptor antagonist is reduced in pancreatic islets of patients with type 2 diabetes mellitus, and high glucose concentrations induce the production of interleukin-1beta in human pancreatic beta cells, leading to impaired insulin secretion, decreased cell proliferation, and apoptosis. METHODS: In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human interleukin-1-receptor antagonist) subcutaneously once daily for 13 weeks and 36 patients to receive placebo. At baseline and at 13 weeks, all patients underwent an oral glucose-tolerance test, followed by an intravenous bolus of 0.3 g of glucose per kilogram of body weight, 0.5 mg of glucagon, and 5 g of arginine. In addition, 35 patients underwent a hyperinsulinemic-euglycemic clamp study. The primary end point was a change in the level of glycated hemoglobin, and secondary end points were changes in beta-cell function, insulin sensitivity, and inflammatory markers. RESULTS: At 13 weeks, in the anakinra group, the glycated hemoglobin level was 0.46 percentage point lower than in the placebo group (P=0.03); C-peptide secretion was enhanced (P=0.05), and there were reductions in the ratio of proinsulin to insulin (P=0.005) and in levels of interleukin-6 (P<0.001) and C-reactive protein (P=0.002). Insulin resistance, insulin-regulated gene expression in skeletal muscle, serum adipokine levels, and the body-mass index were similar in the two study groups. Symptomatic hypoglycemia was not observed, and there were no apparent drug-related serious adverse events. CONCLUSIONS: The blockade of interleukin-1 with anakinra improved glycemia and beta-cell secretory function and reduced markers of systemic inflammation. (ClinicalTrials.gov number, NCT00303394 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, early interventions with insulin therapy in newly diagnosed T2D ( 83 ), with targeted anti-inflammatory therapy using an IL-1β antagonist ( 84 ), and with GLP-1 receptor agonists ( 85 ) have demonstrated that β-cell dysfunction can be reversed temporarily.”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [84]
In the citing paper
“improved glucose control required fewer glucose-lowering agents, including insulin”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“a greater proportion of participants achieved a HbA1c <7%135”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [135]
In the citing paper
“A benefit for anakinra was also shown in a small, randomized trial of 70 patients with type 2 diabetes109.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
In the citing paper
“However, the clinical study was still small and was not designed to determine optimal dosing, duration of use or long-term outcomes in disease control.”
From Sterile inflammation: sensing and reacting to damage (2010) · cites this paper as [109]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Mootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Biologic basis for interleukin-1 in disease.
Dinarello, C. (1996) · Blood · doi:10.1182/blood.v87.6.2095.bloodjournal8762095 · Cited by 4,344
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2017) · Journal of Clinical Investigation · doi:10.1172/jci92172 · Cited by 1,114
Self-citationGlucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets
Maedler, K., Sergeev, P., Ris, F., Oberholzer, J., Joller-Jemelka, H. I., Spinas, G. A., Kaiser, N., Halban, P. A., & Donath, M. Y. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215318 · Cited by 1,005
Self-citationNeonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1β Inhibition
Goldbach-Mansky, R., Dailey, N. J., Canna, S. W., Gelabert, A., Jones, J., Rubin, B. I., Kim, H. J., Brewer, C., Zalewski, C., Wiggs, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055137 · Cited by 930
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Cited by
Items 701–800 of 1,001
Wang, T., Xu, H. Y., Dong, R., Wu, S., Guo, Y., & Wang, D. (2023) · Food Research International · doi:10.1016/j.foodres.2023.112567 · Cited by 53
Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
Bertrand, M.-J., & Tardif, J. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269743 · Cited by 59
Inflammasomes: Caspase-1-Activating Platforms with Critical Roles in Host Defense
Vande Walle, L., & Lamkanfi, M. (2011) · Frontiers in Microbiology. · doi:10.3389/fmicb.2011.00003 · Cited by 50
Adipocyte GPX4 protects against inflammation, hepatic insulin resistance and metabolic dysregulation
Schwärzler, J., Mayr, L., Radlinger, B., Grabherr, F., Philipp, M., Texler, B., Grander, C., Ritsch, A., Hunjadi, M., Enrich, B., et al. (2022) · International Journal of Obesity · doi:10.1038/s41366-022-01064-9 · Cited by 57
The contribution of sterile inflammation to the fatty liver disease and the potential therapies
Shaker, M. E. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112789 · Cited by 53
The NLRP3 inflammasome, a target for therapy in diverse disease states
Cook, G. P., Savic, S., Wittmann, M., & McDermott, M. (2010) · European Journal of Immunology · doi:10.1002/eji.200940162 · Cited by 53
G6PD Up-Regulation Promotes Pancreatic β-Cell Dysfunction
Lee, J.-W., Choi, A. H., Ham, M., Kim, J.-W., Choe, S. S., Park, J., Lee, G. Y., Yoon, K., & Kim, J. B. (2011) · Endocrinology · doi:10.1210/en.2010-0606 · Cited by 55
The Baf60c/Deptor Pathway Links Skeletal Muscle Inflammation to Glucose Homeostasis in Obesity
Meng, Z., Wang, L., Xiao, Y., & Lin, J. D. (2014) · Diabetes · doi:10.2337/db13-1061 · Cited by 55
Innate immunity in CKD-associated vascular diseases
Zewinger, S., Schumann, T., Fliser, D., & Speer, T. (2015) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfv358 · Cited by 53
Eye on the horizon: The metabolic landscape of the RPE in aging and disease
Hansman, D., Du, J., Casson, R. J., & Peet, D. J. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101306 · Cited by 55
Yagihashi, S., Inaba, W., & Mizukami, H. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12424 · Cited by 51
Sultan, A., Strodthoff, D., Robertson, A.-K., Paulsson-Berne, G., Fauconnier, J., Parini, P., Rydén, M., Thierry-Mieg, N., Johansson, M. E., Chibalin, A. V., et al. (2009) · Circulation Research · doi:10.1161/circresaha.108.190280 · Cited by 50
Lipocalin‐2 is induced by interleukin‐1β in murine adipocytes in vitro
Sommer, G., Weise, S., Kralisch, S., Lössner, U., Blüher, M., Stümvoll, M., & Faßhauer, M. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21980 · Cited by 50
Inflammatory and Prothrombotic States in Obese Children of European Descent
Stoppa‐Vaucher, S., Dirlewanger, M., Meier, C. A., de Moerloose, P., Reber, G., Roux‐Lombard, P., Combescure, C., Saudan, S., & Schwitzgebel, V. (2012) · Obesity · doi:10.1038/oby.2012.85 · Cited by 56
Amin, A. H., Choi, S. K., Galán, M., Kassan, M., Partyka, M., Kadowitz, P. J., Henrion, D., Trebak, M., Belmadani, S., & Matrougui, K. (2011) · The Journal of Pathology · doi:10.1002/path.3960 · Cited by 50
“It is well established that in type II diabetes, the most prevalent metabolic disease worldwide, chronic inflammation contributes to insulin resistance [31].”
BackgroundBurke, S. J., Karlstad, M. D., Regal, K. M., Sparer, T. E., Lu, D., Elks, C. M., Grant, R. W., Stephens, J. M., Burk, D. H., & Collier, J. J. (2015) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2015.03.007 · Cited by 53
Insulitis in human diabetes: a histological evaluation of donor pancreases
Lundberg, M., Seiron, P., Ingvast, S., Korsgren, O., & Skog, O. (2016) · Diabetologia · doi:10.1007/s00125-016-4140-z · Cited by 51
Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients
Kataria, Y., Ellervik, C., & Mandrup-Poulsen, T. R. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00743-6 · Cited by 56
Self-citationInterleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis
Gonçalves, N. P., Vieira, P., & Saraiva, M. J. (2014) · Amyloid · doi:10.3109/13506129.2014.927759 · Cited by 52
The Stress Axis in Obesity and Diabetes Mellitus: An Update
Gianotti, L., Belcastro, S., D’Agnano, S., & Tassone, F. (2021) · Endocrines · doi:10.3390/endocrines2030031 · Cited by 59
Börgeson, E., & Godson, C. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00318 · Cited by 51
A clear and present danger: inflammasomes DAMPing down disorders of pregnancy
Khan, R. N., & Hay, D. P. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu059 · Cited by 54
Wang, G.-X., Cho, K. W., Uhm, M., Hu, C.-R., Li, S., Cozacov, Z., Xu, A. E., Cheng, J., Saltiel, A. R., Lumeng, C. N.-K., et al. (2013) · Diabetes · doi:10.2337/db13-1139 · Cited by 61
Matuschik, L., Riabov, V., Schmuttermaier, C., Sevastyanova, T. N., Weiß, C., Klüter, H., & Kzhyshkowska, J. G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031385 · Cited by 52
Biomarkers and immune-modulating therapies for Type 2 diabetes
Brooks‐Worrell, B., Narla, R. R., & Palmer, J. P. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.002 · Cited by 50
A Signal for the Caspase-1 Inflammasome Free of TLR
Dinarello, C. A. (2007) · Immunity · doi:10.1016/j.immuni.2007.04.005 · Cited by 48
Impact of Diabetes in Blood-Testis and Blood-Brain Barriers: Resemblances and Differences
Alves, M. G., Oliveira, P. F., Socorro, S., & Moreira, P. I. (2012) · Current Diabetes Reviews · doi:10.2174/157339912803529896 · Cited by 50
Dharmadhikari, G., Stolz, K., Hauke, M., Morgan, N. G., Varki, A. P., de Koning, E. J. P., Kelm, S., & Maedler, K. (2017) · Scientific Reports · doi:10.1038/srep45319 · Cited by 54
Ruscitti, P., Ursini, F., Cipriani, P., Greco, M., Alvaro, S., Vasiliki, L., Benedetto, P. D., Carubbi, F., Berardicurti, O., Gulletta, E., et al. (2019) · Medicine · doi:10.1097/md.0000000000014587 · Cited by 53
“Of note, a clinical trial and its extension pointed out a beneficial role of IL-1 blockade on patients with T2D, reducing A1c and improving the associated metabolic derangement.([43,44])”
BackgroundEffects of colchicine in adults with metabolic syndrome: A pilot randomized controlled trial
Demidowich, A. P., Levine, J. A., Onyekaba, G. I., Khan, S. M., Chen, K. Y., Brady, S. M., Broadney, M. M., & Yanovski, J. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13702 · Cited by 50
Henriksbo, B. D., Tamrakar, A. K., Xu, J., Duggan, B. M., Cavallari, J. F., Phulka, J. S., Stämpfli, M. R., Ashkar, A. A., & Schertzer, J. D. (2019) · Diabetes · doi:10.2337/db18-0999 · Cited by 48
Involvements of long noncoding RNAs in obesity‐associated inflammatory diseases
Wijesinghe, S. N., Nicholson, T., Tsintzas, K., & Jones, S. W. (2021) · Obesity Reviews · doi:10.1111/obr.13156 · Cited by 47
The Role of NLRP3 Inflammasome in Pneumococcal Infections
Surabhi, S., Cuypers, F., Hammerschmidt, S., & Siemens, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.614801 · Cited by 50
Henderson, C., & Goldbach‐Mansky, R. T. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.02.013 · Cited by 51
Farkas, G. J., Burton, A. M., McMillan, D. W., Sneij, A. M., & Gater, D. R. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071088 · Cited by 50
Gröger, M., Matsuo, K., Arash, E. H., Pereira, A., Guillou, D. L., Pino, C., Telles-Silva, K. A., Maher, J. J., Hsiao, E. C., & Willenbring, H. (2023) · Nature Communications · doi:10.1038/s41467-023-39311-w · Cited by 48
Glucose regulation of β ‐cell stress in type 2 diabetes
Leibowitz, G., Bachar-Wikström, E., Shaked, M., Sinai, A., Ketzinel‐Gilad, M., Cerasi, E., & Kaiser, Ν. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01280.x · Cited by 51
Immune intervention in type 1 diabetes
Michels, A. W., & Eisenbarth, G. S. (2011) · Seminars in Immunology · doi:10.1016/j.smim.2011.07.003 · Cited by 47
CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study
Di Prospero, N. A., Artis, E., Andrade‐Gordon, P., Johnson, D. L., Vaccaro, N., Xi, L., & Rothenberg, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12309 · Cited by 45
Anakinra treatment in patients with gout and type 2 diabetes
Vitale, A., Cantarini, L., Rigante, D., Bardelli, M., & Galeazzi, M. (2014) · Clinical Rheumatology · doi:10.1007/s10067-014-2601-7 · Cited by 47
“found that anakinra could improve hyperglycemia and beta-cell secretory function in patients affected with T2D [18].”
BackgroundEffect of Periodontal Treatment on HbA1c among Patients with Prediabetes
Kocher, T., Holtfreter, B., Petersmann, A., Eickholz, P., Hoffmann, T. K., Kaner, D., Kim, T., Meyle, J., Schlagenhauf, U., Doering, S., et al. (2018) · Journal of Dental Research · doi:10.1177/0022034518804185 · Cited by 52
Current perspectives on the interleukin‐1 family as targets for inflammatory disease
Hernandez-Santana, Y., Giannoudaki, E., León, G., Lucitt, M. B., & Walsh, P. T. (2019) · European Journal of Immunology · doi:10.1002/eji.201848056 · Cited by 48
Adipose tissue dysfunction and its effects on tumor metabolism
Diedrich, J. D., Chkourko, H., & Podgorski, I. (2015) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2014-0045 · Cited by 53
“Circulating adiponectin is shown to be decreased in patients with T2DM, cardiovascular disease, liver disease, and hypertension [73–75].”
BackgroundZheng, Y., Zhang, D., Zhang, L., Fu, M., Zeng, Y., & Russell, R. (2013) · Gene · doi:10.1016/j.gene.2013.07.082 · Cited by 47
Rafiq, S., Melzer, D., Weedon, M. N., Lango, H., Saxena, R., Scott, L. J., the DIAGRAM Consortium, Palmer, C. N. A., Morris, A. D., McCarthy, M. I., et al. (2008) · Diabetologia · doi:10.1007/s00125-008-1160-3 · Cited by 46
Herder, C., Nuotio, M.-L., Shah, S., Blankenberg, S., Brunner, E. J., Carstensen, M., Gieger, C., Grallert, H., Jula, A., Kähönen, M., et al. (2014) · Diabetes · doi:10.2337/db14-0731 · Cited by 46
Yoshitake, R., Hirose, Y., Murosaki, S., & Matsuzaki, G. (2020) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2020-040 · Cited by 47
NLRP3 inflammasome activation, metabolic danger signals, and protein binding partners
Leu, S., Tsang, Y.-L., Ho, L., Yang, C.-C., Shao, A., Chang, C.-Y., Lin, H.-K., Tsai, P.-J., Sung, J., & Tsai, Y.-S. (2023) · Journal of Endocrinology · doi:10.1530/joe-22-0184 · Cited by 50
Is immunity a mechanism contributing to statin-induced diabetes?
Henriksbo, B. D., & Schertzer, J. D. (2015) · Adipocyte · doi:10.1080/21623945.2015.1024394 · Cited by 47
Huang, F., Chan, A. O. O., Lo, R. C., Rashid, A., Wong, D. K.-H., Cho, C., Lai, C., & Yuen, M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.03.031 · Cited by 48
Collino, M., Benetti, E., Rogazzo, M., Mastrocola, R., Yaqoob, M. M., Aragno, M., Thiemermann, C., & Fantozzi, R. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.014 · Cited by 51
Impact of Islet Autoimmunity on the Progressive β-Cell Functional Decline in Type 2 Diabetes
Brooks-Worrell, B. M., Boyko, E. J., & Palmer, J. P. (2014) · Diabetes Care · doi:10.2337/dc14-0961 · Cited by 45
Is Diabetes Mellitus a Continuous Spectrum?
Brooks‐Worrell, B., & Palmer, J. P. (2011) · Clinical Chemistry · doi:10.1373/clinchem.2010.148270 · Cited by 57
Passacquale, G., Di Giosia, P., & Ferro, A. (2016) · Cardiovascular Research · doi:10.1093/cvr/cvv227 · Cited by 45
Parasite excretory‐secretory products and their effects on metabolic syndrome
Crowe, J., Lumb, F. E., Harnett, M. M., & Harnett, W. (2017) · Parasite Immunology · doi:10.1111/pim.12410 · Cited by 45
Li, J., Li, J., Ni, J., Zhang, C., Jia, J., Wu, G., Sun, H., & Wang, S. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.752512 · Cited by 50
An islet in distress: β cell failure in type 2 diabetes
Ogihara, T., & Mirmira, R. G. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00021.x · Cited by 50
Fang, S. C., Mehta, A. J., Alexeeff, S., Gryparis, A., Coull, B. A., Vokonas, P., Christiani, D. C., & Schwartz, J. D. (2012) · Environmental Health Perspectives · doi:10.1289/ehp.1103982 · Cited by 54
“IL-1β is produced by pancreatic β cells, and it is thought that high glucose levels lead to the production of β cells, which in turn leads to the production and release of IL-1β (Larsen et al. 2007).”
BackgroundThe Multifaceted Role of the Inflammasome in Inflammatory Bowel Diseases
Lissner, D., & Siegmund, B. (2011) · The Scientific World JOURNAL · doi:10.1100/tsw.2011.139 · Cited by 51
COVID-19: Diabetes Perspective—Pathophysiology and Management
Dallavalasa, S., Tulimilli, S. V., Janhavi, P., Ramachandra, R., Madhunapantula, S. V., & Veeranna, R. P. (2023) · Pathogens · doi:10.3390/pathogens12020184 · Cited by 47
Zgutka, K., Tkacz, M., Tomasiak, P., Piotrowska, K., Ustianowski, P., Pawlik, A., & Tarnowski, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111409 · Cited by 47
“They have demonstrated beneficial effects on metabolic parameters, reducing glycated haemoglobin (HbA1c), increasing insulin sensitivity and β -cell secretion, together with an improvement in inflammatory markers, in patients with T2DM [55,56] and with a history of myocardial infarction [57–63].”
BackgroundIL-1 and atherosclerosis: a murine twist to an evolving human story
Rader, D. J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61163 · Cited by 43
Abecassis, A., Schuster, R., Shahaf, G., Ozeri, E., Green, R., Ochayon, D. E., Rider, P., & Lewis, E. C. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.17 · Cited by 47
How biologics targeting the IL‐1 system are being considered for the treatment of type 2 diabetes
Böni‐Schnetzler, M., & Donath, M. Y. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04297.x · Cited by 42
Self-citationPharmacological treatment options for cryopyrin-associated periodic syndromes
Landmann, E., & Walker, U. A. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1338946 · Cited by 49
Evidence against a role for NLRP3-driven islet inflammation in db/db mice
Kammoun, H. L., Allen, T. L., Henstridge, D. C., Barre, S., Coll, R. C., Lancaster, G. I., Cron, L., Reibe, S., Chan, J. Y., Bensellam, M., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.02.001 · Cited by 46
The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus
Donath, M. Y., & Mandrup-Poulsen, T. R. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0783 · Cited by 46
“As IL-1β clearly has a key role in the pathogenesis of diabetes mellitus, the availability of anakinra enabled us to conduct a clinical trial of IL-1 receptor antagonism in patients with type 2 diabetes mellitus”
BackgroundSelf-citationSaltevo, J. T., Laakso, M., Jokelainen, J. J., Keinanen-Kiukaanniemi, S. M., Kumpusalo, E., & Vanhala, M. J. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.831 · Cited by 48
Khan, M. M. (2008) · Springer eBooks · doi:10.1007/978-0-387-77976-8_2 · Cited by 54
Banerjee, M., Bid, H., Konwar, R., & Agrawal, C. (2008) · Indian Journal of Medical Sciences · doi:10.4103/0019-5359.42021 · Cited by 56
Bessueille, L., Fakhry, M., Hamade, E., Badran, B. M., & Magne, D. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.07.045 · Cited by 48
Production and function of IL-12 in islets and beta cells
Taylor, D., Weaver, J. R., Grzesik, W., Chakrabarti, S., Green-Mitchell, S. M., Imai, Y., Kuhn, N. S., & Nadler, J. L. (2012) · Diabetologia · doi:10.1007/s00125-012-2732-9 · Cited by 44
Inflammasome-Mediated Autoinflammatory Disorders
Wilson, S. P., & Cassel, S. L. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.09.2209 · Cited by 50
Salivary Proteins Associated with Periodontitis in Patients with Type 2 Diabetes Mellitus
Chan, H. H., Rahim, Z. H. A., Jessie, K., Hashim, O. H., & Taiyeb-Ali, T. B. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13044642 · Cited by 52
Pulmonary and systemic inflammatory responses to intra-amniotic IL-1α in fetal sheep
Kallapur, S. G., Kramer, B. W. W., Nitsos, I., Pillow, J. J., Collins, J. J. P., Polglase, G. R., Newnham, J. P., & Jobe, A. H. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00446.2010 · Cited by 48
Galloway, J. B., Hyrich, K. L., Mercer, L., Dixon, W. G., Watson, K. D., Lunt, M., Symmons, D. P. M., & on behalf of the British Society for Rheumatology Biologics Register (2011) · Rheumatology · doi:10.1093/rheumatology/ker146 · Cited by 44
Nowotny, B., Zahiragic, L., Bierwagen, A., Kabisch, S., Groener, J. B., Nowotny, P., Fleitmann, A. K., Herder, C., Pacini, G., Erlund, I., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3457-8 · Cited by 45
Altering β-cell number through stable alteration of miR-21 and miR-34a expression
Backe, M. B., Novotny, G. W., Christensen, D. P., Grunnet, L. G., & Mandrup-Poulsen, T. (2014) · Islets · doi:10.4161/isl.27754 · Cited by 44
“Cytokine antagonists are under study as novel antidiabetic treatments.(5,6) MicroRNAs (miRNAs) are small noncoding ~22 nucleotide transcripts regulating protein expression by binding to complementary mRNA binding regions thereby targeting them for either degradation or translational inhibition.”
BackgroundSelf-citationBaskar, S., Klein, A. L., & Zeft, A. (2016) · Cardiology Research and Practice · doi:10.1155/2016/7840724 · Cited by 43
IL-1 Antagonism in men with metabolic syndrome and low testosterone: a randomized clinical trial
Ebrahimi, F., Urwyler, S. A., Straumann, S., Doerpfeld, S., Bernasconi, L., Neyer, P., Schuetz, P., Mueller, B., Donath, M. Y., & Christ-Crain, M. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00739 · Cited by 42
Self-citationAssociation of Variation in the Interleukin-1 Gene Family with Diabetes and Glucose Homeostasis
Luotola, K., Pääkkönen, R., Alanne, M., Lanki, T., Moilanen, L., Surakka, I. L., Pietilä, A., Kähönen, M. A. P., Nieminen, M. S., Kesäniemi, Y. A., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0666 · Cited by 47
Inflammation as a Sensor of Metabolic Stress in Obesity and Type 2 Diabetes
Donath, M. Y. (2011) · Endocrinology · doi:10.1210/en.2011-1691 · Cited by 41
Self-citationRoell, M. K., Issafras, H., Bauer, R. J., Michelson, K. S., Mendoza, N., Vanegas, S., Gross, L. M., Larsen, P. D., Bedinger, D., Bohmann, D. J., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.115790 · Cited by 45
The anti‐interleukin‐1 in type 1 diabetes action trial—background and rationale
Pickersgill, L., & Mandrup-Poulsen, T. R. (2009) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.960 · Cited by 43
Self-citationGenovese, M. C., Burmester, G. R., HAGINO, O. R., Thangavelu, K., Iglesias‐Rodriguez, M., John, G. S., González-Gay, M. Á., Mandrup-Poulsen, T. R., & Fleischmann, R. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02229-5 · Cited by 46
Self-citationNALP3 inflammasome activation in protein misfolding diseases
Shi, F., Kouadir, M., & Yang, Y. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.05.011 · Cited by 45
Rønn, S. G., Börjesson, A., Bruun, C., Heding, P. E., Frobøse, H., Mandrup-Poulsen, T. R., Karlsen, A. E., Rasschaert, J., Sandler, S., & Billestrup, N. (2008) · Diabetologia · doi:10.1007/s00125-008-1090-0 · Cited by 44
“This suggests that beta cell apoptosis during type 1 and type 2 diabetes mellitus may be mediated by cytokines [36, 37 ].”
BackgroundSelf-citationEl‐Sherbini, S. M., Shahen, S. M., Mosaad, Y. M., Abdelgawad, M. S., & Talaat, R. M. (2013) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmt003 · Cited by 42
IL-1 cytokine family members and NAFLD: Neglected in metabolic liver inflammation
Tilg, H., & Moschen, A. R. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.007 · Cited by 46
“Treatment of type 2 diabetes patients with recombinant human IL-1Ra improves glycemic control, clearly highlighting the role of inflammation in type 2 diabetes and insulin resistance [15].”
BackgroundMechanistic insights into pancreatic beta-cell mass regulation by glucose and free fatty acids
Oh, Y. S. (2015) · Anatomy & Cell Biology · doi:10.5115/acb.2015.48.1.16 · Cited by 49
Knudsen, S. H., & Pedersen, B. K. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0642-1 · Cited by 41
PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells
Yang, J., Wang, C., Li, J., Burkhardt, B. R., Robert, C. E., Wilson, C. G., Gao, Z., & Wolf, B. A. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.08.008 · Cited by 41
Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist
Klementiev, B., Li, S., Korshunova, I., Dmytriyeva, O., Pankratova, S., Walmod, P. S., Kjær, L. K., Dahllöf, M. S., Lundh, M., Christensen, D. P., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-27 · Cited by 43
Self-citationNeutrophils Require SHP1 To Regulate IL-1β Production and Prevent Inflammatory Skin Disease
Croker, B. A., Lewis, R. S., Babon, J. J., Mintern, J. D., Jenne, D. E., Metcalf, D., Zhang, J., Cengia, L. H., O’Donnell, J. A., & Roberts, A. W. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1002702 · Cited by 41
Zhao, Y. L., Jiang, Z., & Guo, C. (2011) · Autoimmunity Reviews · doi:10.1016/j.autrev.2011.09.003 · Cited by 44
Wang, N., Tian, X., Chen, Y., Tan, H.-Q., Xie, P.-J., Shao-jun, C., Fu, Y., Chen, Y., Xu, W., & Wei, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14408-7 · Cited by 42
Function of Pro-Resolving Lipid Mediator Resolvin E1 in Type 2 Diabetes
Sima, C., Paster, B. J., & Dyke, T. E. V. (2018) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018026750 · Cited by 45
Nunemaker, C. S. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2846570 · Cited by 47
Sahraoui, A., Kloster‐Jensen, K., Ueland, T., Korsgren, O., Foss, A. E., & Scholz, H. (2013) · Cell Transplantation · doi:10.3727/096368913x667529 · Cited by 41
“In clinical studies, improved glycemia in patients treated with anakinra correlated with improved b-cell secretory capacity (20,21).”
BackgroundRusso, H. M., Wickenheiser, K. J., Luo, W., Öhman, M. K., Franchi, L., Wright, A. P., Bodary, P. F., Núñez, G., & Eitzman, D. T. (2010) · Circulation Research · doi:10.1161/circresaha.110.218651 · Cited by 41
Metadata
- Authors
- Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y.
- Affiliations
- University Hospital Zurich (CH)
- Steno Diabetes Centers (DK)
- University of Zurich (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-04-12
- Volume
- 356
- Issue
- 15
- Pages
- 1517-1526
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2024378513
- Cited by
- 1,798
- References
- 29
- Citations by year
- 2026: 41 · 2025: 47 · 2024: 61 · 2023: 75 · 2022: 89 · 2021: 97 · 2020: 84 · 2019: 83 · 2018: 87 · 2017: 77 · 2016: 111 · 2015: 113 · 2014: 135 · 2013: 141 · 2012: 132
- FWCI
- 93.91
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- anakinra, interleukin-1 receptor antagonist, type 2 diabetes, IL-1β, beta-cell function, insulin secretion, HbA1c, systemic inflammation, interleukin-6, C-reactive protein, C-peptide, hyperinsulinemic-euglycemic clamp, insulin resistance, adipokines
- MeSH terms
- Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha, Blood Glucose, C-Reactive Protein, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Gene Expression Regulation, Glucose Tolerance Test, Heat-Shock Proteins, Glycated Hemoglobin, Humans, Insulin Resistance, Male, Middle Aged, Recombinant Proteins, RNA, Messenger, Transcription Factors, Interleukin-6, Body Mass Index, Receptors, Interleukin-1, Insulin-Secreting Cells, Glucose Transporter Type 4, Interleukin 1 Receptor Antagonist Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.